(KROS) Keros Therapeutics - Performance -69.2% in 12m
KROS performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-60.45%
#86 in Peer-Group
Rel. Strength
5.47%
#7021 in Stock-Universe
Total Return 12m
-69.18%
#158 in Peer-Group
Total Return 5y
-64.50%
#73 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | 49.0 |
| High / Low | USD |
|---|---|
| 52 Week High | 70.00 USD |
| 52 Week Low | 9.55 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 38.91 |
| Buy/Sell Signal +-5 | -0.24 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: KROS (-69.2%) vs XBI (-10.8%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
0.31% | 66.4% | 81.3% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-11.3% | -10.9% | 137% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
-2.26% | -8.02% | 39.9% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
2.47% | 33.7% | 4.38% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| KMDA NASDAQ Kamada |
12.2% | 64.2% | 3.4% | 25.5 | 22.8 | 0.91 | 48.1% | 3.93% |
| NBIX NASDAQ Neurocrine Biosciences |
1.42% | -10.5% | -0.06% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| PTCT NASDAQ PTC Therapeutics |
1.94% | 59.9% | -1.58% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
6.88% | 35.5% | 16% | 28.9 | 15.1 | 0.63 | -62.1% | -19.3% |
Performance Comparison: KROS vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for KROS
| Total Return (including Dividends) | KROS | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -3.78% | 3.18% | 4.52% |
| 3 Months | 32.38% | 2.36% | 10.25% |
| 12 Months | -69.18% | -10.75% | 14.16% |
| 5 Years | -64.50% | -24.51% | 116.91% |
| Trend Score (consistency of price movement) | KROS | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -77.9% | 30.9% | 79.1% |
| 3 Months | 32.5% | 63.2% | 91.7% |
| 12 Months | -65.1% | -83.8% | 44% |
| 5 Years | -28.6% | -52.9% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th41.50 | -6.74% | -7.94% |
| 3 Month | %th83.50 | 29.33% | 20.07% |
| 12 Month | %th21.00 | -65.47% | -73.00% |
| 5 Years | %th62.50 | -52.97% | -83.63% |
FAQs
Does Keros Therapeutics (KROS) outperform the market?
No,
over the last 12 months KROS made -69.18%, while its related Sector, the SPDR S&P Biotech (XBI) made -10.75%.
Over the last 3 months KROS made 32.38%, while XBI made 2.36%.
Performance Comparison KROS vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
KROS vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -4.4% | -8.3% | -18.9% | -83% |
| US NASDAQ 100 | QQQ | -5.1% | -9.3% | -20.3% | -84% |
| German DAX 40 | DAX | -5.3% | -4.2% | -34.1% | -100% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -3.8% | -6.3% | -14.9% | -86% |
| Hongkong Hang Seng | HSI | -4.8% | -10.6% | -36.1% | -105% |
| India NIFTY 50 | INDA | -4.8% | -6.1% | -19.9% | -69% |
| Brasil Bovespa | EWZ | -3.7% | -7.3% | -40.5% | -80% |
KROS vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -5.6% | -10.7% | -25.2% | -97% |
| Consumer Discretionary | XLY | -3.9% | -5.7% | -10.9% | -90% |
| Consumer Staples | XLP | -0.9% | -2.6% | -17.8% | -78% |
| Energy | XLE | -1.1% | -8.3% | -16.3% | -66% |
| Financial | XLF | -4.2% | -6.3% | -22.1% | -97% |
| Health Care | XLV | -3.3% | -5.5% | -12.2% | -63% |
| Industrial | XLI | -4% | -6.9% | -25.7% | -93% |
| Materials | XLB | -3.1% | -6.1% | -19.7% | -72% |
| Real Estate | XLRE | 0.3% | -3.3% | -17.2% | -81% |
| Technology | XLK | -5.2% | -12.2% | -21.1% | -80% |
| Utilities | XLU | -2.1% | -4.8% | -22.6% | -93% |
| Aerospace & Defense | XAR | -6.3% | -13.4% | -40% | -121% |
| Biotech | XBI | -2.9% | -7% | -6.1% | -58% |
| Homebuilder | XHB | -3.1% | -7.7% | -8.4% | -70% |
| Retail | XRT | -2.2% | -5.9% | -11.5% | -76% |
KROS vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 2.1% | -12.8% | -11.7% | -59% |
| Natural Gas | UNG | -0.2% | -7.2% | -5.5% | -69% |
| Gold | GLD | 1.2% | -2.3% | -38.9% | -109% |
| Silver | SLV | -0.9% | -11.4% | -37.2% | -91% |
| Copper | CPER | -5.3% | -12.4% | -37.3% | -85% |
KROS vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -2.7% | -5.6% | -15.1% | -70% |
| iShares High Yield Corp. Bond | HYG | -2.5% | -5.3% | -18.4% | -80% |